Document is current
Any future updates will be listed below
-
Authors
Henry, Christopher R.
Walter, Scott D.
Chang, Peter Y.
Warrow, David J.
Naeini, Parisa Emami
Blinder, Kevin J.
Brevetti, Teresa
Yassine, Mohamed
Dacey, Mark S.
Chu, David S.
Raiji, Veena R.
Rifkin, Lana M.
Shah, Milan
Singer, Michael A.
-
Funding
Funding for this research was provided by:
Bausch + Lomb
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 7 October 2024
First Online: 23 October 2024
Declarations
:
: Not applicable; this is a physician survey completed by the authors of this manuscript; therefore, no ethics approval or participant consent is required.
: Not applicable.
: Competing interests: CRH reports being a consultant for Allergan, Alimera, Bausch + Lomb, Clearside Biomedical, Inc., and EyePoint Pharmaceuticals. SDW reports being a speaker for Apellis, Bausch + Lomb, Genentech/Roche, Regeneron, and Spark Therapeutics. SDW reports being a consultant for Allergan, Astellis/Iveric Bio, Bausch + Lomb, Castle Biosciences, EyePoint Pharmaceuticals/Alimera, Genentech/Roche, Ideaya Biosciences, Lupin, Novartis, and Regeneron. PEN reports receiving research and consulting fees from EyePoint Pharmaceuticals and Genentech. PEN is supported by the Knights Templar Eye Foundation, Inc. Career Starter grant. MAS reports receiving consulting fees from Aerie, Alimera, Allegro, Allergan, Eyepoint, Genentech, Kodiak, Novartis, Regeneron, and Santen; serving on the speakers’ bureau for Allergan, Apellis, Genentech, Mallinckrodt, Novartis, Regeneron, and Spark; and performing contracted research for Aerie, Allegro, Allergan, DRCR, Genentech, Icon, Ionis, KalVista, Kodiak, Novartis, Opthea, Optos, Regeneron, Santen, Senju, and Sydnexis. Survey participants (CRH, SDW, PYC, DJW, PEN, KJB, MSD, DSC, VRR, LMR, MS, and MAS) received an honorarium from Bausch & Lomb Americas, Inc. TB and MY are employees of Bausch + Lomb, Bridgewater, NJ.
